Advertisement

Topics

Drug Approvals Reports

14:03 EDT 22nd May 2018 | BioPortfolio

Ovarian Cancer: Update Bulletin [January 2018] [Report Updated: 01012018] Prices from USD $1095

This edition presents key opinion leader KOL views on recent developments in the ovarian cancer market. Topics covered include: US Food and Drug Administration FDA acceptance for Genentech's supplemental Biologics License Application sBLA for Avastin bevacizumab and chemotherapy, followed by Avastin alone, in the frontline setting; EU approval of Zejula niraparib; Tesaro/Merck Co. for the treatme...

NORTH AMERICA BOTANICAL PLANT DERIVATIVE DRUG MARKET FORECAST 20182026 [Report Updated: 01011970] Prices from USD $1250

KEY FINDINGSThe North America botanical and plant derivative drug market is predicted to expand at a CAGR of 7.57%, for the forecast period of 20182026. MARKET INSIGHTSSeveral noted vendors in North America are increasingly promoting the deployment of botanical drugs and products as key dietary supplements. However, only a few products have been approved by the United States Food and Drug Admini...

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy Drug Approvals market research data and corporate reports here